TScan Therapeutics up on FDA nod to initiate study of cancer therapies

Tscan Therapeutics

23/01/2023 13:18

** Shares of drug developer TScan Therapeutics Inc  TCRX.O 
rise 12.3% to $2.36 premarket
    ** Company says U.S. health regulator cleared its
applications seeking to initiate study for three of its
experimental cancer therapies
    ** TCRX plans to initiate and provide data for its most
advanced cancer therapy study by the end of 2023
    ** Shares of TScan fell ~66% last year
 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com))